Stay updated with breaking news from Thyroid Associated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Data presented at ENDO 2022 indicates low rates of hyperglycemic events were easily controlled, did not cause treatment disruption and were most often seen in patients with pre-existing diabetes ---- A separate poster presentation examined response to TEPEZZA in patients who were mildly hypothyroid and found outc...
-- Poster presentation will share results from the Phase 2 and Phase 3 trials on blood glucose levels in patients with Thyroid Eye Disease (TED) -- -- Three-time Olympic gold medalist Gail Devers will
-- Nationwide campaign spotlights mental health impact of living with TED -- For Mental Health Awareness Month and Healthy Vision Month in May, Horizon Therapeutics plc (Nasdaq: HZNP) is partnering
-- Teprotumumab is marketed under the brand name TEPEZZA in the United States -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical
-- Comprehensive OPTIC-X trial results published in Ophthalmology, including new long-term follow-up data Horizon Therapeutics plc (Nasdaq: HZNP) today announced additional data supporting the long-term